SUMMARY
The basis of the anti-ischemic therapy is a combination of two complementary concepts – hemodynamic and metabolic. They are implemented due to the different mechanisms of drug actions. “Kapikor” medicine was developed by the Latvian scientists. The medicine is the original regulator of the vascular endothelial function with a binary mechanism of action, which is a combination of Meldonium and ?-butyrobetaine (GBB). The results of the experimental research of the median effective dose (ED50) of “Kapikor” by the cerebroprotective effect, as well as the results of studying its effect on pathologically changed brain tissues on the model of hemic hypoxia caused by introduction of the sodium nitrite (sodium nitriteinduced hypoxia), are presented in the article. On the background of hemic hypoxia in rats “Kapikor” in the doses of 25, 50 and 100 mg/kg had the dose-dependent cerebroprotective effect, which was the most pronounced in the dose of 100 mg/ kg. The cerebroprotective effect of “Kapikor” in all doses showed increase in the life expectancy of animals, decrease in the intensity of free radical and destructive processes in the nervous tissue. By the cerebroprotective activity ED50 of “Kapikor” was 56.5 ± 8.5 mg/kg. It is the most optimal dose of “Kapikor” in the experimental study of its cerebroprotective properties. This is the basis for further in-depth pharmacological study of “Kapikor” medicine for the purpose of its introduction into clinical practice as an original medicine with a binary mechanism of action.